SCHEMBL15818317

SCHEMBL15818317

COC(=O)c1ccncc1NCc1ccc(C)o1

nearest known ligand 0.48

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
▸ KDM4C Q9H3R0 17/20 0.48
▸ KDM4E B2RXH2 6/20 0.48
▸ KDM6B O15054 5/20 0.48
▸ KDM4A O75164 3/20 0.48
▸ KDM4D Q6B0I6 3/20 0.48
▸ KDM5C P41229 2/20 0.48
▸ ALDH1A1 P00352 3/20 0.46
▸ GLA P06280 1/20 0.46
▸ GAA P10253 1/20 0.46
▸ PKM P14618 2/20 0.46
▸ TSHR P16473 2/20 0.46
▸ MAPT P10636 1/20 0.46
▸ HPGD P15428 1/20 0.46
▸ POLB P06746 1/20 0.44
▸ MAPK1 P28482 1/20 0.44
▸ SLCO1B1 Q9Y6L6 1/20 0.44
▸ KDM5B Q9UGL1 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL15818589 0.87 KDM4C (0.63) KDM4CKDM4EKDM6BKDM4AKDM4D
SCHEMBL1715953 0.79 KDM4C (0.61) KDM4CKDM4EKDM6BKDM4AKDM4D
SCHEMBL2384943 0.76 KDM4E (0.45) KDM4EALDH1A1GLAGAAPKM
SCHEMBL10659182 0.76 NPC1 (0.40) KDM4CKDM4EKDM6BKDM4AKDM4D
SCHEMBL13909025 0.75 ALDH1A1 (0.49) KDM4EALDH1A1GLAGAAPKM
SCHEMBL15839871 0.74 KDM4C (0.56) KDM4CKDM4EKDM6BKDM4AKDM4D
SCHEMBL15839866 0.74 KDM4C (0.56) KDM4CKDM4EKDM6BKDM4AKDM4D
SCHEMBL15839872 0.74 KDM4C (0.56) KDM4CKDM4EKDM6BKDM4AKDM4D
SCHEMBL15839873 0.72 KDM4C (0.53) KDM4CKDM4EKDM6BKDM4AKDM4D
SCHEMBL16542216 0.72 KDM4E (0.62) KDM4CKDM4EKDM6BALDH1A1GLA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 49 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230286917-A1 HISTONE DEMETHYLASE INHIBITORS CELGENE QUANTICEL RESEARCH, INC. (US) 2023-09-14 — — US disclosed
US-20230286917-A1 HISTONE DEMETHYLASE INHIBITORS CELGENE QUANTICEL RESEARCH, INC. (US) 2023-09-14 — — US disclosed
US-11639333-B2 Histone demethylase inhibitors CELGENE QUANTICEL RESEARCH, INC (US) 2023-05-02 — — US disclosed
US-11639333-B2 Histone demethylase inhibitors CELGENE QUANTICEL RESEARCH, INC (US) 2023-05-02 — — US disclosed
US-11214542-B2 Histone demethylase inhibitors CELGENE QUANTICEL RESEARCH, INC. (US) 2022-01-04 — — US disclosed
US-11214542-B2 Histone demethylase inhibitors CELGENE QUANTICEL RESEARCH, INC. (US) 2022-01-04 — — US disclosed
US-20210009520-A1 HISTONE DEMETHYLASE INHIBITORS CELGENE QUANTICEL RESEARCH, INC. (US) 2021-01-14 — — US disclosed
US-20210009520-A1 HISTONE DEMETHYLASE INHIBITORS CELGENE QUANTICEL RESEARCH, INC. (US) 2021-01-14 — — US disclosed
US-10807956-B2 Histone demethylase inhibitors CELGENE QUANTICEL RESEARCH, INC. (US) 2020-10-20 — — US disclosed
US-10807956-B2 Histone demethylase inhibitors CELGENE QUANTICEL RESEARCH, INC. (US) 2020-10-20 — — US disclosed
US-9085534-B2 Histone demethylase inhibitors Quanticel Pharmaceuticals, Inc. (US) 2015-07-21 — — US disclosed
US-9085534-B2 Histone demethylase inhibitors Quanticel Pharmaceuticals, Inc. (US) 2015-07-21 — — US disclosed
US-20150119397-A1 HISTONE DEMETHYLASE INHIBITORS CELGENE QUANTICEL RESEARCH, INC. 2015-04-30 — — US disclosed
US-20150119397-A1 HISTONE DEMETHYLASE INHIBITORS CELGENE QUANTICEL RESEARCH, INC. 2015-04-30 — — US disclosed
US-8952151-B2 Histone demethylase inhibitors Quanticel Pharmaceuticals, Inc. (US) 2015-02-10 — — US disclosed
US-8952151-B2 Histone demethylase inhibitors Quanticel Pharmaceuticals, Inc. (US) 2015-02-10 — — US disclosed
US-20140213591-A1 HISTONE DEMETHYLASE INHIBITORS Quanticel Pharmaceuticals, Inc. (US) 2014-07-31 — — US disclosed
US-20140213591-A1 HISTONE DEMETHYLASE INHIBITORS Quanticel Pharmaceuticals, Inc. (US) 2014-07-31 — — US disclosed
WO-2014100818-A1 HISTONE DEMETHYLASE INHIBITORS Quanticel Pharmaceuticals, Inc. (US) 2014-06-26 — — WO disclosed
WO-2014100818-A1 HISTONE DEMETHYLASE INHIBITORS Quanticel Pharmaceuticals, Inc. (US) 2014-06-26 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-11214542-B2 Histone demethylase inhibitors KDM1B, KDM5A, KDM1A KDM4C 18/4885KDM4E 26/4885KDM6B 23/4885
US-10807956-B2 Histone demethylase inhibitors KDM1B, KDM5A, KDM1A KDM4C 18/4885KDM4E 26/4885KDM6B 23/4885
US-20230286917-A1 HISTONE DEMETHYLASE INHIBITORS KDM1B, KDM5A, KDM1A KDM4C 18/4885KDM4E 26/4885KDM6B 23/4885
US-20210009520-A1 HISTONE DEMETHYLASE INHIBITORS KDM1B, KDM5A, KDM1A KDM4C 18/4885KDM4E 26/4885KDM6B 23/4885
US-11639333-B2 Histone demethylase inhibitors KDM1B, KDM5A, KDM1A KDM4C 18/4885KDM4E 26/4885KDM6B 23/4885
US-20150119397-A1 HISTONE DEMETHYLASE INHIBITORS KDM1B, KDM5A, KDM1A KDM4C 18/4885KDM4E 26/4885KDM6B 23/4885
US-20140213591-A1 HISTONE DEMETHYLASE INHIBITORS KDM1B, KDM5A, KDM1A KDM4C 18/4885KDM4E 26/4885KDM6B 23/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback